Intraocular Neovascular Syndromes

Diabetes mellitus, occlusion of central retinal vein, or prematurity can all be associated with retinal ischemia and intraocular neovascularization, which may result in vitreous hemorrhages, retinal detachment, neovascular glaucoma, and blindness (165,166). Expression of VEGF mRNA spatially and temporally correlates with neovascularization in several animal models of retinal ischemia (32,167,168). Elevations of VEGF levels in the aqueous and vitreous of human eyes with proliferative retinopathy...

References

Carmeliet, P. and Jain, R.K., Angiogenesis in cancer and other diseases, Nature, 407, 249, 2000. 2. Ferrara, N., Gerber, H.P., and LeCouter, J., The biology of VEGF and its receptors, Nat Med, 9, 669, 2003. 3. Jain, R.K. and Carmeliet, P.F., Vessels of death or life, Sci Am, 285, 38, 2001. 4. Jain, R.K., Molecular regulation of vessel maturation, Nat Med, 9, 685, 2003. 5. Folkman, J., Tumor angiogenesis therapeutic implications, N Engl J Med, 285, 1182, 1971. 6. Dvorak, H.F., Vascular...

Clinical Trials in Cancer Patients with VEGF Inhibitors

Several VEGF inhibitors are undergoing clinical development as anticancer agents. These inhibitors include a humanized variant of and anti-VEGF monoclonal antibody that was used in early proof-of-concept studies bevacizumab Avastin 153 , an anti-VEGFR-2 antibody 138 and various small molecules inhibiting VEGFR-2 signal transduction 134,135 , a VEGF receptor chimeric protein 143 for recent reviews, see 154,155 . The pivotal trial with bevacizumab that led to FDA approval was a large randomized...

AntiVEGF Antibody Bevacizumab Avastin

The most successful approach to date to therapeutically target VEGF is the use of a humanized monoclonal antibody against VEGF, bevacizumab Avastin ,276 which was U.S. Food and Drug Administration FDA approved for use as a first-line therapy for metastatic colorectal cancer in February 2004 specifically, bevacizumab in combination with intravenous 5-FU-based chemotherapy is a new treatment option.277 Furthermore, bevacizumab also significantly prolonged time to progression of disease in...

Part I

Chapter 1 Strategies to Prolong the Nonangiogenic Dormant State of Human Cancer 3 Chapter 2 Vascular Endothelial Growth Factor Basic Biology and Clinical Chapter 3 Angiogenesis in Solid Chapter 4 Pathophysiologic Role of VEGF in Hematologic Klaus Podar, Shaji Kumar, Dharminder Chauhan, and Kenneth C. Anderson Chapter 5 Tumor Microenvironment and Cheryl H. Baker and Isaiah J. Fidler Targeting Angiogenesis for Cancer Chapter 6 Tyrosine Kinase Inhibitors of Janessa J. Laskin and Alan B. Sandler...

Clinical Latency In Cancer Recurrence Following A Primary Tumor Treatment

Cancer recurrence after treatment of the primary tumor is a major cause of mortality among cancer patients. It may take years to decades before local or distant i.e., metastatic recurrence becomes clinically detectable as cancer. This disease-free period is a time of uncertainty for patients who appear cured. For example, Demicheli et al.1 have demonstrated two hazardous peaks of breast cancer recurrence in patients undergoing mastectomy alone without adjuvant therapy. In a group of 1173...

Editors

Davis is president and chief executive officer of ApoCell, Inc., an innovative molecular diagnostic company located near the world famous Texas Medical Center, Houston, Texas. Dr Davis has a BS in biochemical and biophysical sciences and earned his PhD in cancer biology and toxicology at the University of Texas Graduate School of Biomedical Sciences and the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr Davis continued his postgraduate training at M.D....